Fungi · Scientific monograph
Poria cocos
Fu Ling / Tuckahoe / Indian Bread
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Immunological Research, CNS Depression Research, Inflammatory Pathways
Research overview
Historical use
One of the most widely used fungi in Traditional Chinese Medicine, mentioned as a primary herb in the Shen Nong Ben Cao Jing (c. 100 CE). Known as 'Fu Ling', used to calm the mind (shen), strengthen the spleen and stomach, promote urination, and resolve dampness. A core component of many classical TCM formulas (e.g., Liu Wei Di Huang Wan, Si Jun Zi Tang).
Modern research context
Beta-pachymaran and pachymic acids are the primary studied bioactives; renoprotective pharmacology of triterpenoids has been comprehensively characterised [2]. A clinical study demonstrated improved sleep quality with Poria cocos extract, aligning with its traditional use for insomnia [1]. Polysaccharides show gut microbiome-modulating properties in antibiotic-associated diarrhoea models [3]. Anti-tumour activity of Poria cocos polysaccharide (PCP) is supported by preclinical mechanistic data [4]. Effects on metabolic dysfunction-associated fatty liver disease have been investigated [5].
Adverse effects
Generally very well tolerated. Rare GI symptoms at high doses. Rare hypersensitivity reactions.
Contraindications
Diuretics — additive diuretic effect (Poria has mild diuretic properties). Sedatives/anxiolytics — potential additive CNS depression. No absolute contraindications well-established.
Clinical and phytochemical data
Used part
Sclerotium (underground mass)
Primary active compounds
Pachymaran (beta-1,3-glucan)
Pachymic acid (lanostane triterpenoid)
Tumulosic acid
Dehydropachymic acid
Poriacocos polysaccharides (PCP)
Ergosterol
Mechanism of action
Pachymaran activates macrophages and NK cells via Dectin-1/TLR-4. Pachymic acid inhibits NF-κB pathway, reducing pro-inflammatory cytokines (IL-6, TNF-α, COX-2). Diuretic action attributed to direct renal tubular effects. Sedative effects involve positive modulation of GABA-A receptor (animal data only).
Pharmacokinetics
Absorption
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — In vitro permeability of pachymic acid (lanostane triterpenoid) was characterised in Caco-2 human intestinal epithelial cell monolayers, suggesting transcellular passive diffusion with moderate permeability [1]. No human oral bioavailability data available. Pachymic acid absorbed orally; reaches systemic circulation. Pachymaran (high MW) has limited systemic absorption. Detailed human PK data limited.
Distribution
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Pachymaran (polysaccharide) preferentially targets GALT and spleen; limited systemic absorption. Pachymic acid (triterpenoid) is lipophilic; distributes to liver and adipose tissue. Plasma protein binding of triterpenoids estimated >80% by analogy with structurally related compounds. No human clinical PK distribution studies.
Metabolism
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Pachymic acid undergoes hepatic CYP450-mediated metabolism. Polysaccharides partially fermented by intestinal microbiota.
Excretion
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Renal excretion of triterpenoid metabolites; fecal for polysaccharides.
Safety and interactions
Drug interactions
Lack of clinical studies prevents interaction grading. Unknown safety profile with concomitant drug use.
Toxicity
LD50 >10 g/kg (oral, mice) for whole extract. Long-term traditional use at standard TCM doses has not been associated with documented serious adverse effects; formal long-term human clinical data are insufficient. No significant organ toxicity has been identified in preclinical studies.
Special precautions
Pregnancy
Traditionally used cautiously during pregnancy. Insufficient controlled safety data — avoid concentrated preparations.
Lactation
No data on breast milk excretion. Avoid supplemental doses during breastfeeding.
Hepatic impairment
No hepatotoxicity documented. Standard monitoring with concentrated preparations.
Renal impairment
Mild diuretic properties; use with caution in patients on diuretic therapy. No specific dose adjustment data.
Sources and references
- [1] - Kim H., "Efficacy of Poria Cocos Extract on Sleep Quality Enhancement: A Clinical Perspective with Potential Neurological Implications.", Nutrients, 2023, PMID: 37836526
- [2] - Guo ZY., "Poria cocos: traditional uses, triterpenoid components and their renoprotective pharmacology.", Acta Pharmacol Sin, 2025, PMID: 39482471
- [3] - Xu H., "Poria cocos Polysaccharide Ameliorated Antibiotic-Associated Diarrhea in Mice via Regulating Gut Microbiota.", Int J Mol Sci, 2023, PMID: 36674937
- [4] - Li X., "Molecular basis for Poria cocos mushroom polysaccharide used as an antitumour drug in China.", J Cell Mol Med, 2019, PMID: 30444050
- [5] - He J., "Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via regulating lipid metabolism.", Front Pharmacol, 2022, PMID: 36278226